DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for connective tissue disease — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleConnective tissue disease maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for connective tissue disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta receptor 2 (TGFBR2) — TGFBR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-methoxypyridin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5QIN · 1.57 Å · ligand N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide (J2V). Experimental structure, not a prediction.
What the evidence adds up to
The 1992 and 1961 entries are book reviews, not original research. They contain no patient data, no drug interventions, and no clinical outcomes. The 2017 abstract defines connective tissue diseases as systemic autoimmune disorders with multisystemic involvement, characterised by self-reactive T cells, autoantibodies, and inflammation. It offers no treatment results, no survival figures, and no sample sizes.
No drug is mentioned in any of these abstracts. There are no response rates, no survival data, and no comparisons between treated and untreated groups. The 2017 abstract is a general description of immunogenetics, not a clinical trial or a repurposing study.
What is missing is any clinical evidence at all. There are no trials, no patient cohorts, no drug exposures, and no outcome measures. Without original research that tests a specific drug in connective tissue disease patients, no conclusion about efficacy or repurposing can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medicine of Ukraine · 2021 · 2 citations · open access
Connective tissue dysplasia: features of clinical manifestations, diagnosis and treatment
AbstractConnective tissue dysplasia (CTD) is one of the complex issues of modern medicine. It is a unique developmental anomaly that includes a large heterogeneous group of conditions. The systemic nature of the lesion is due to the wide distribution of connective tissue in the body. Dysplastic changes in the connective tissue of various organs and systems are diagnosed when a patient has a set of signs that do not fit into any of the differentiated diseases. The article presents a review of the literature on the definition, causes of development, clinical forms, general approaches to the diagnosis and treatment of CTD.
AbstractREVIEWS OF BOOKS PATHOLOGICAL BASIS OF THE CONNECTIVE TISSUE DISEASES. By D. L. Gardner. £145.00. Sevenoaks: Edward Arnold, 1992. K. WHALEY K. WHALEY Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, Volume 31, Issue 12, December 1992, Page 862, https://doi.org/10.1093/rheumatology/31.12.862-a Published: 01 December 1992
Connective tissue and diseases of connective tissue. Volume 86 of Annals of the New York Academy of Sciences. Edited by Franklin N. Furness. 9 × 6 in. Pp. 258. Illustrated. 1960. New York: Academy of Sciences. No price given
AbstractConnective tissue and diseases of connective tissue. Volume 86 of Annals of the New York Academy of Sciences. Edited by Franklin N. Furness. 9 × 6 in. Pp. 258. Illustrated. 1960. New York: Academy of Sciences. No price given Get access Connective Tissue and Diseases of Connective Tissue. Volume 86 of Annals of the New York Academy of Sciences. Edited by Franklin N Furness. 9 × 6 in. Pp. 258. Illustrated. 1960. New York: Academy of Sciences. No price given. British Journal of Surgery, Volume 48, Issue 210, January 1961, Page 469, https://doi.org/10.1002/bjs.18004821042 Published: 06 December 2005
Sohag Medical Journal · 2017 · 0 citations · open access
Immunogenetics of some connective tissue disorders
AbstractConnective tissue diseases (CTDs) are systemic autoimmune disorders characterized by a large spectrum of clinical features and multisystemic involvement. Connective tissue disease is any disease that has the connective tissues of the body as a target of pathology. Connective tissue is any type of biological tissue with an extensive extracellular matrix that supports, binds together, and protects organs. These tissues form a framework, or matrix, for the body, and are composed of two major structural protein molecules: collagen and elastin. Autoimmunity involves the loss of normal immune homeostasis such that the organism produces an abnormal response to its own self tissue. The hallmark of autoimmune diseases generally involves the presence of self-reactive T cells, autoantibodies and inflammation
Immunopharmacology and Immunotoxicology · 2025 · 0 citations
Therapeutic effect of nintedanib in orbital fibroblasts in patients with Graves’ orbitopathy
AbstractBACKGROUND: Nintedanib is a potent antifibrotic angiokinase inhibitor approved for various fibrotic lung diseases. Potential therapeutic efficacy of nintedanib in various inflammatory diseases is under investigation. In this study, we investigated the therapeutic effect of nintedanib on adipogenesis and fibrosis in orbital fibroblasts in patients with Graves' orbitopathy (GO). METHODS: Primary orbital fibroblasts were cultured from orbital connective tissue of patients with GO and healthy controls. The cells were pretreated with nintedanib before stimulation with either interleukin (IL)-1β, transforming growth factor (TGF)-β, insulin-like growth factor-1, or IL-11. Fibrosis-related and intracellular signaling protein expressions were assessed using western blotting. Hyaluronan and procollagen concentrations were quantified using enzyme-linked immunosorbent assay. Adipogenesis was quantified by Oil Red O staining and the levels of adipogenic transcription factors were determined by Western blot. RESULTS: TGF-β-induced fibronectin and collagen 1/3 protein expression was abrogated by nintedanib treatment. Nintedanib decreased the phosphorylation of signal transducer and activator of transcription 3, SMAD 2/3, Akt, c-Jun N-terminal kinase, and extracellular regulated protein kinase. Exposure to nintedanib hindered adipocyte differentiation and expression of adipogenic transcription factors, including peroxisome proliferator-activated receptor γ, CCAAT/enhancer-binding protein α/β, adipocyte protein 2, adiponectin, and leptin. Additionally, nintedanib reduced hyaluronan and procollagen secretion. CONCLUSIONS: . These findings indicate the potential therapeutic efficacy of nintedanib in GO management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
